Emerging Roles of LncRNAs in the EZH2-regulated Oncogenic Network

Area of Science:

• Epigenetics
• Molecular Biology
• Oncology

Background:

• Cancer therapies increasingly target epigenetic mechanisms.
• Enhancer of zeste homolog 2 (EZH2) is crucial for Polycomb repressive complex 2 (PRC2)-mediated histone methylation (H3K27me3), a transcriptional repressor.
• Elevated EZH2 levels correlate with poor prognosis in various cancers, functioning both within and outside the PRC2 complex.

Purpose of the Study:

• To review the functional interactions between EZH2 and long non-coding RNAs (lncRNAs).
• To elucidate how lncRNAs regulate EZH2 expression at multiple levels.
• To summarize oncogenic pathways co-regulated by lncRNAs and EZH2.

Main Methods:

• Literature review of studies on EZH2, lncRNAs, and cancer.
• Analysis of EZH2's PRC2-dependent and -independent functions.
• Examination of lncRNA-mediated regulation of EZH2 expression (transcriptional, post-transcriptional, post-translational).
• Review of specific oncogenic pathways (e.g., Wnt/β-catenin, p53) involving lncRNAs and EZH2.

Main Results:

• Functional interactions between EZH2 and lncRNAs dictate EZH2's roles in cancer.
• lncRNAs modulate EZH2 expression via transcriptional, post-transcriptional, and post-translational mechanisms.
• Cooperative regulation of oncogenic pathways, including Wnt/β-catenin and p53, by lncRNAs and EZH2 is evident.

Conclusions:

• lncRNAs are integral components of the EZH2-driven oncogenic network.
• Understanding lncRNA-EZH2 interactions offers promising avenues for cancer therapy development.
• Further exploration of this network is crucial for uncovering novel therapeutic targets.